Azathioprine for people with multiple sclerosis

This is a protocol for a Cochrane Review (intervention). The objectives are as follows:

The objectives of the review are to estimate the benefits and harms of:

  • azathioprine (AZA) compared with placebo or other disease -modifying treatments (DMTs) as first-choice treatment for relapsing forms of multiple sclerosis (MS);

  • AZA compared with placebo or other DMTs for relapsing forms of MS when switching from another DMT;

  • AZA compared with placebo or other DMTs as first-choice treatment for progressive forms of MS; and

  • AZA compared with placebo or other DMTs for progressive forms of MS when switching from another DMT.

This is a protocol.